S. Starling Marshall
Areas of Focus
Overview
When clients face complex commercial and tax disputes, they rely on S. Starling Marshall as their advocate and counselor. Starling is a trial lawyer with over 15 years of experience who has successfully represented clients before federal and state courts, arbitration panels, and administrative tribunals. Drawing on her years of government service and private practice, she guides clients toward business-minded solutions throughout all phases of an investigation or litigation.
Career & Education
- Department of Justice: Tax Division
Court of Federal Claims Section, Trial Attorney, 2009–2016 - U.S. District Court for the Southern District of New York
Law Clerk, Honorable Victor Marrero, 2008–2009
- Department of Justice: Tax Division
- Emory University, B.A., 2002
- Fordham University School of Law, J.D., cum laude, 2005
- New York
- U.S. District Court for the Southern District of New York
- U.S. Court of Federal Claims
Professional Activities and Memberships
- J. Edgar Murdock Inn of Court, 2013–Present
- Dave Nee Foundation, President of the Board of Directors, 2013–Present
- Fordham Law Alumni Association of Washington, President of the Board of Directors, 2012–2016
- Federal Bar Association – New York Chapter, 2016–Present; Taxation Steering Committee, 2012–Present
- American University's Washington College of Law, Adjunct Professor, 2012–2016
S. Starling's Insights
Client Alert | 4 min read | 03.25.25
Federal Circuit Affirms Deductibility of Hatch-Waxman Litigation Expenses
In a significant decision for generic drug manufacturers, the Federal Circuit recently affirmed that litigation expenses incurred in defending Hatch-Waxman patent lawsuits are deductible as ordinary and necessary business expenses under the Internal Revenue Code (IRC). The ruling in Actavis Laboratories FL, Inc. v. United States, No. 23-1320 (Fed. Cir. Mar. 21, 2025), resolves a key tax dispute, allowing tax deductions for these expenses in the year they are incurred rather than capitalizing them over time. This outcome provides clarity and potential tax benefits for qualifying businesses navigating the interplay of patent litigation and FDA drug approvals.
Speaking Engagement | 03.24.25
"IRS Enforcement Priorities," PLI Tax Controversy 2025: Navigating the New Enforcement
Press Coverage | 03.19.25
Press Coverage | 01.01.25
Recognition
- The National Law Journal: Tax Law Trailblazer, 2023
- Crain’s New York Business: Notable Woman in Law, 2023
- The Best Lawyers in America: Lawyer of the Year, New York, 2022
- The Federal Bar Association: Section of Taxation Chair, 2021-2022
- American College of Tax Counsel: Fellow
S. Starling's Insights
Client Alert | 4 min read | 03.25.25
Federal Circuit Affirms Deductibility of Hatch-Waxman Litigation Expenses
In a significant decision for generic drug manufacturers, the Federal Circuit recently affirmed that litigation expenses incurred in defending Hatch-Waxman patent lawsuits are deductible as ordinary and necessary business expenses under the Internal Revenue Code (IRC). The ruling in Actavis Laboratories FL, Inc. v. United States, No. 23-1320 (Fed. Cir. Mar. 21, 2025), resolves a key tax dispute, allowing tax deductions for these expenses in the year they are incurred rather than capitalizing them over time. This outcome provides clarity and potential tax benefits for qualifying businesses navigating the interplay of patent litigation and FDA drug approvals.
Speaking Engagement | 03.24.25
"IRS Enforcement Priorities," PLI Tax Controversy 2025: Navigating the New Enforcement
Press Coverage | 03.19.25
Press Coverage | 01.01.25
Insights
- |
03.29.24
New York Law Journal
- |
09.26.23
The Journal of Federal Agency Action
Rescission
|10.01.20
Commercial Litigation in New York State Courts, Fifth Edition, Thomson Reuters
Corporate – Blockchain’s Awareness Problem—and How to Solve It
|02.26.20
Crowell & Moring's Litigation Forecast 2020
TEI Seattle
|12.10.24
International Tax Series: International Tax Controversy Update
|05.23.24
"Privilege, Penalties and Good Faith Across Jurisdictions,” ABA’s 24th Annual U.S. and Europe Tax Practice Trends, Munich, Germany
|04.11.24
“Ethics and Privilege – What’s Trending?,” 52nd Annual Conference of the USA Branch of the International Fiscal Association, New York, NY
|03.22.24
2023 Notable Women In Law: S. Starling Marshall
|06.20.23
Crain's New York Business
- |
03.04.24
Crowell & Moring’s Crypto Digest
S. Starling's Insights
Client Alert | 4 min read | 03.25.25
Federal Circuit Affirms Deductibility of Hatch-Waxman Litigation Expenses
In a significant decision for generic drug manufacturers, the Federal Circuit recently affirmed that litigation expenses incurred in defending Hatch-Waxman patent lawsuits are deductible as ordinary and necessary business expenses under the Internal Revenue Code (IRC). The ruling in Actavis Laboratories FL, Inc. v. United States, No. 23-1320 (Fed. Cir. Mar. 21, 2025), resolves a key tax dispute, allowing tax deductions for these expenses in the year they are incurred rather than capitalizing them over time. This outcome provides clarity and potential tax benefits for qualifying businesses navigating the interplay of patent litigation and FDA drug approvals.
Speaking Engagement | 03.24.25
"IRS Enforcement Priorities," PLI Tax Controversy 2025: Navigating the New Enforcement
Press Coverage | 03.19.25
Press Coverage | 01.01.25